Node.js released updates fixing a critical DoS flaw caused by async_hooks stack crashes, tracked as CVE-2025-59466, impacting ...
1d
'His demise was set up': Mom lured toddler's dad to his death ahead of contentious custody hearing
Allyah Martin was sentenced to 15 years in a Louisiana state prison for allegedly luring her child's father to his death ...
What are the differences between how AI systems handle JavaScript-rendered or interactively hidden content compared to ...
This is a summary of: Liu. H. et al. Viral RNA blocks circularization to evade host codon usage control. Nature https://doi.org/10.1038/s41586-025-09809-y (2025).
Abstract: Many recent image restoration methods use Transformer as the backbone network and redesign the Transformer blocks. Differently, we explore the parameter-sharing mechanism over Transformer ...
Additionally, Recursion plans to present updated clinical data from the TUPELO trial during a webinar scheduled for December 8, 2025. This presentation will provide further insights into the safety ...
Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best fundamentally strong penny stocks to buy according to analysts. On December 19, TheFly reported that Cathie Wood’s ARK Investment has ...
Cathie Wood’s ARK ETF published their daily trades for Friday, December 19th, 2025, showcasing significant activity in several key stocks. Leading the trades was a substantial sale of 23,110 shares of ...
Abstract: Online collision-free trajectory generation within a shared workspace is fundamental for most multirobot applications. However, many widely-used methods based on model predictive control ...
Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...
Recursion Pharmaceuticals, Inc. (RXRX) recently received a notable upgrade from JP Morgan analyst Eric Joseph, who shifted his rating to “Overweight” on December 17, 2025. This upgrade comes as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback